May 29, 2019 8:00 am EDT Emerald Bioscience Secures “All Fields” Licenses for Cannabinoid Derivatives Developed by University of Mississippi
May 13, 2019 8:00 am EDT Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference
Apr 22, 2019 7:30 am EDT Emerald Bioscience Announces Ophthalmology Scientific Advisory Board Members
Apr 8, 2019 8:30 am EDT Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
Apr 1, 2019 7:30 am EDT Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
Mar 25, 2019 8:00 am EDT Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
Mar 18, 2019 7:30 am EDT Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
Mar 12, 2019 7:30 am EDT Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues